We have also demonstrated that by combining a single administration of Ad5-TRP2 with subsequent peritumoral administrations of PMG5, we can significantly increase the efficacy of the Ad5-TRP2 cancer vaccine in treating the murine melanoma model. This evidence concerns the gene DCT and melanoma.